👤 João F. Machado

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
3
Articles
3
Name variants
Also published as: Aline Maria Machado, Rafael Pereira Machado
articles
Marcos V. Palmeira-Mello, Tamara Teixeira, Analu R. Costa +11 more · 2025 · Inorganic Chemistry Frontiers · Royal Society of Chemistry · added 2026-05-01
📄 PDF DOI: 10.1039/d5qi00546a
Biometal
Henrique Vieira Reis Silva, Guilherme Álvaro Ferreira da Silva, Bruno Zavan +6 more · 2023 · Polyhedron · Elsevier · added 2026-05-01
📄 PDF DOI: 10.1016/j.poly.2022.116267
Biometal
Jonas F. Schlagintweit, Christian H. G. Jakob, Nicola L. Wilke +12 more · 2021 · Journal of Medicinal Chemistry · ACS Publications · added 2026-04-20
The synthesis and antiproliferative activity of Mes- and iPr-substituted gold(I) bis(1,2,3-triazol-5-ylidene) complexes in various cancer cell lines are reported, showing nanomolar IC50 val Show more
The synthesis and antiproliferative activity of Mes- and iPr-substituted gold(I) bis(1,2,3-triazol-5-ylidene) complexes in various cancer cell lines are reported, showing nanomolar IC50 values of 50 nM (lymphoma cells) and 500 nM (leukemia cells), respectively (Mes < iPr). The compounds exclusively induce apoptosis (50 nM to 5 μM) instead of necrosis in common malignant blood cells (leukemia cells) and do not affect non-malignant leucocytes. Remarkably, the complexes not only overcome resistances against the well-established cytostatic etoposide, cytarabine, daunorubicin, and cisplatin but also promote a synergistic effect of up to 182% when used with daunorubicin. The present results demonstrate that gold(I) bis(1,2,3-triazol-5-ylidene) complexes are highly promising and easily modifiable anticancer metallodrugs. Show less
no PDF DOI: 10.1021/acs.jmedchem.1c01021
Au anticancer